z-logo
Premium
In vitro production of human antibodies specifically reactive with human gastric cancer cells of established lines and autologous tissues
Author(s) -
Takayama Tadatoshi,
Sakabe Takashi,
Fujii Masashi,
Yamada El,
Uno Masatsune,
Ono Yasushi
Publication year - 1987
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930360313
Subject(s) - cancer , antibody , antigen , cancer cell , lymph node , medicine , cell culture , cancer research , immunology , in vitro , microbiology and biotechnology , pathology , biology , biochemistry , genetics
Human lymphocytes derived from regional lymph nodes adjacent to the primary gastric cancer were transformed with Epstein‐Barr virus (EBV) to establish lymphoblastoid cell lines secreting human antibodies reactive with cell surface antigens expressed on the gastric cancer cells. The EBV transformation technique was applied to lymph node lymphocytes obtained from 4 gastric cancer patients. As a result of mass screening with the radioactive cell binding assay for the production of anti‐gastric cancer related antibodies, one culture (TGc‐106) among 1,400 microcultures was identified to secrete human antibody specifically reactive with an established human gastric cancer cell line as target (MKN‐45). Furthermore, it was demonstrated with the autologous assay system by the histoimmuno‐fluorescence method that cell surface antigens of autologous gastric cancer cells could be clearly defined with human antibody from one culture (TEb‐079) out of 470 microcultures established from a gastric cancer patient (GCP‐26); there was no reactivity against the surrounding normal cells constructing the gastric wall. The immunoglobulin class of the human antibodies produced both in TGc‐106 and TEb‐079 was determined from immunodiffusion tests to be IgM.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here